LH · Healthcare

LABCORP HOLDINGS INC.

Ranked earnings events from SEC filings, earnings calls, press releases and news. Full Picture: what to focus on this earnings window

10-Q · 2026-08-05

• Liquidity and Debt PositionImportance 65 · Surprise 82
  Cash and cash equivalents declined to $141.8 million at June 30, 2026, from $647.3 million at June 30, 2025, after a six-month cash decrease of $390.5 million. Operating cash flow was $637.0 million, while investing…
• Capital Return ProgramImportance 65 · Surprise 60
  Labcorp repurchased $251.8 million more common stock during the first six months of 2026 than in the comparable 2025 period. The Board had authorized $378.6 million of remaining repurchases at June 30, 2026, then…
• Interest Rate and Refinancing ExposureImportance 64 · Surprise 42
  On March 20, 2026, Labcorp entered into a $750.0 million term loan maturing March 20, 2028. The loan proceeds were used on June 1, 2026, to redeem the company’s outstanding 1.55% senior notes due 2026, with any…
• Manufacturing and CapacityImportance 61 · Surprise 66
  Labcorp invested $252.6 million in capital expenditures during the first six months of 2026, up 23.9% from $203.9 million in the prior-year period. Spending represented 3.5% of revenue and supported projects in the…
• Equity Method LossesImportance 59 · Surprise 82
  Second-quarter equity method loss increased to $6.2 million from $1.7 million, a 259.6% year-over-year increase. Six-month equity method loss rose to $11.3 million from $2.0 million, a 475.0% increase. The losses…
• Operating Income and MarginsImportance 54 · Surprise 40
  Second-quarter 2026 operating income increased 14.5% to $451.6 million from $394.5 million. Dx operating income rose 8.2% to $522.6 million, while its operating margin improved approximately 50 basis points to 18.0%…
• Operating Expense TrendsImportance 54 · Surprise 40
  Second-quarter SG&A decreased 0.3% to $577.2 million, while SG&A declined to 15.5% of revenue from 16.4% in 2025 because of revenue growth. Six-month SG&A increased 0.3% to $1,128.2 million, but remained 15.5% of…
• Capital ExpendituresImportance 53 · Surprise 48
  Six-month capital expenditures increased to $252.6 million from $203.9 million, a 23.9% year-over-year increase. Capital expenditures represented 3.5% of six-month revenue in 2026. Spending supported growth in the core…
• Capital Expenditure ProgramImportance 53 · Surprise 48
  Labcorp used $252.6 million for capital expenditures in the six months ended June 30, 2026, compared with $203.9 million in the prior-year period. Capital expenditures represented 3.5% of revenue and were directed…
• Headcount / RestructuringImportance 49 · Surprise 66
  Second-quarter 2026 restructuring and other charges increased 21.2% to $5.1 million from $4.1 million. The 2026 quarterly charges included $5.2 million of severance and personnel costs, $1.7 million of facility costs,…
• Acquisition / Partnership / DivestitureImportance 47 · Surprise 60
  On June 28, 2026, Labcorp agreed to acquire select assets of an outreach laboratory services business for approximately $155.0 million. The transaction was expected to close in the third quarter of 2026, subject to…
• Healthcare Regulation ChangesImportance 44 · Surprise 60
  On July 4, 2025, the U.S. government enacted the OBBBA, which changes Medicaid and Affordable Care Act regulations and federal healthcare funding. Labcorp stated that reduced insurance coverage could decrease…
• Revenue Performance and MixImportance 43 · Surprise 32
  Second-quarter 2026 revenue increased 5.8% year over year to $3,731.1 million from $3,527.3 million, driven by 4.2% organic growth, 1.2% net acquisition growth, and 0.4% favorable foreign currency translation. Dx…
• Gross Margin DriversImportance 43 · Surprise 32
  Second-quarter 2026 cost of revenues increased 5.6% to $2,619.1 million from $2,481.1 million. Cost of revenues declined to 70.2% of revenue from 70.3% year over year, implying a 10-basis-point improvement in gross…
• End-Market Demand TrendsImportance 43 · Surprise 32
  Labcorp’s total revenue increased 5.8% year over year to $3,731.1 million in the second quarter of 2026, driven by 4.2% organic growth. Diagnostics (Dx) revenue rose 5.5% to $2,900.7 million, with total requisition…
• Income Tax Rate ChangesImportance 41 · Surprise 48
  Second-quarter income tax expense increased to $87.3 million from $66.4 million. The quarterly effective tax rate increased to 22.6% from 21.8%, primarily because of the jurisdictional mix of earnings. Six-month tax…

News · 2026-08-05

• Net Income and ProfitabilityImportance 48 · Surprise 40
  Labcorp reported Q2 2026 net income attributable to Labcorp Holdings Inc. of $298.7 million. Adjusted EPS increased 14.9% year over year to $4.99, while diluted GAAP EPS was reported at $3.64. Adjusted EPS exceeded the…
• Revenue Performance and MixImportance 43 · Surprise 32
  Labcorp’s Q2 2026 enterprise revenue increased 5.8% year over year to approximately $3.7 billion, or $3,731.1 million. Diagnostics Laboratories and Biopharma Laboratory Services both delivered significant growth during…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  On August 4, 2026, Labcorp announced nationwide availability of Roche’s VENTANA PTEN (SP218) RxDx Assay in the United States. The assay is the first FDA-approved immunohistochemistry companion diagnostic for prostate…

News · 2026-08-04

• Guidance / OutlookImportance 57 · Surprise 60
  Labcorp raised its full-year 2026 revenue and adjusted EPS guidance following Q2 results reported on August 3, 2026. Management expects continued growth and margin expansion, with particular strength in Central…
• Net Income and ProfitabilityImportance 48 · Surprise 40
  Labcorp reported Q2 2026 net income attributable to Labcorp Holdings Inc. of $298.7 million. Adjusted EPS increased 14.9% year over year to $4.99, while diluted GAAP EPS was reported at $3.64. Adjusted EPS exceeded the…
• Revenue Performance and MixImportance 43 · Surprise 32
  Labcorp’s Q2 2026 enterprise revenue increased 5.8% year over year to approximately $3.7 billion, or $3,731.1 million. Diagnostics Laboratories and Biopharma Laboratory Services both delivered significant growth during…
• Product Launch and TransitionImportance 38 · Surprise 60
  Labcorp launched nationwide the Roche VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic for prostate adenocarcinoma. The assay identifies PTEN protein loss in tumors,…
• Regulatory Approval MilestonesImportance 38 · Surprise 60
  On August 4, 2026, Labcorp announced nationwide availability of Roche’s VENTANA PTEN (SP218) RxDx Assay in the United States. The assay is the first FDA-approved immunohistochemistry companion diagnostic for prostate…